HL-1186 tablets to treat moderate to severe pain after surgery.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial testing HL-1186 tablets for adults with moderate to severe acute pain after elective surgery. The study will measure safety, pain relief (using numeric rating scales), and pharmacokinetic parameters compared with placebo. Eligible participants are adults 18–75 years old with BMI between 18 and 30 kg/m2 who report pain of at least 4 on the NRS after specified surgeries. The trial is led by a pharmaceutical sponsor with enrollment at Sichuan Provincial People's Hospital in Chengdu.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years old ≤ age ≤ 75 years old, gender is not limited.
2. 18 kg/m2 ≤ Body Mass Index (BMI) ≤ 30kg/m2.
3. Scheduled to undergo one of the following elective surgeries under general anesthesia: Orthopedic surgery, abdominal surgery, or thoracic surgery.
4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers.
5. Participant reported pain of ≥4 on the NRS.

Exclusion Criteria:

1. Prior history of surgery at the same site, and this may affect pain perception at the surgical site per investigator's judgments.
2. Allergy to any component of the investigational product, to perioperative anesthetic/analgesic/antiemetic agents, or to ≥3 substance allergies.
3. Use of the prohibited medications specified in the protocol within 5 half-lives of the drug (or 7 days if half-life is unknown) prior to randomization, and this may affect pain or scale assessments per investigator's judgments.
4. QTcF ≥450 ms (using Fridericia correction), unstable angina, myocardial infarction, severe arrhythmias (e.g., third-degree atrioventricular block), New York Heart Association (NYHA) class III or higher cardiac function, recurrent asthma, etc., within screen period, and deemed ineligible per investigator's judgments.
5. High bleeding risk conditions: Congenital bleeding disorders (e.g., hemophilia), platelet function abnormalities (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet function abnormalities), active bleeding, etc., and deemed ineligible per investigator's judgments.
6. For female participants: Pregnant or lactating (within 1 year postpartum).
7. Participants with childbearing potential planning conception/sperm/egg donation within 6 months post-treatment, or unwilling to use effective contraception (abstinence, barrier methods, oral contraceptives, intrauterine device, or sterilization).
8. Participants who have participated in other investigational product/device studies within 30 days prior to the screening visit, or are currently enrolled in another study.
9. Judgment by the investigator that the participant should not enter the study due to other conditions.

Where it's running

• Sichuan Provincial People's Hospital
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Renhai Yang
• Email: clinical_trial@hllife.com.cn
• Phone: 021-64311017

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HL-1186 tablets for reducing pain after abdominal surgery

  This trial will test whether HL-1186 tablets reduce moderate to severe pain after abdominal surgery in adults aged 18–75.

  Recruiting Phase 2 Shanghai Huilun Pharmaceutical Co., Ltd. · Changsha, Hunan · NCT07311369

• How opioids affect sleep and mood in adults with cancer pain

  This observational study will test whether sleep and emotional well-being relate to opioid use in adults with moderate to severe cancer pain.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou · NCT07616648

• Patient-reported outcomes after emergency root canal care

  This project will test whether emergency endodontic treatments reduce pain and improve oral health-related quality of life for adults with moderate to severe endodontic pain.

  Recruiting Chulalongkorn University · Bangkok · NCT07192146

• Effects of neuromuscular blocking agents and prone positioning on ARDS

  This study tests if using certain medications and positioning patients on their stomachs can help people with severe breathing problems from ARDS survive better while on a ventilator.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT06212492

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.